208 related articles for article (PubMed ID: 33031633)
1. HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor.
Chang H; Shin YW; Keam B; Kim M; Im SA; Lee ST
Ann Clin Transl Neurol; 2020 Nov; 7(11):2243-2250. PubMed ID: 33031633
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
4. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
[TBL] [Abstract][Full Text] [Related]
5. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
6. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
7. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
Hall KH; Liu Y; Jiang C; Harvey RD
Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
[TBL] [Abstract][Full Text] [Related]
8. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
Iafolla MAJ; Yang C; Chandran V; Pintilie M; Li Q; Bedard PL; Hansen A; Lheureux S; Spreafico A; Razak AA; Hakgor S; Giesler A; Pugh TJ; Siu LL
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554038
[TBL] [Abstract][Full Text] [Related]
9. The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study.
Zhukova N; Orlova R; Malkova A; Kaledina E; Demchenkova A; Naimushina P; Nazarov V; Mazing A; Lapin S; Belyak N; Shoenfeld Y
Crit Rev Immunol; 2022; 42(3):1-9. PubMed ID: 37017622
[TBL] [Abstract][Full Text] [Related]
10. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
11. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
Correale P; Saladino RE; Giannarelli D; Sergi A; Mazzei MA; Bianco G; Giannicola R; Iuliano E; Forte IM; Calandruccio ND; Falzea AC; Strangio A; Nardone V; Pastina P; Tini P; Luce A; Caraglia M; Caracciolo D; Mutti L; Tassone P; Pirtoli L; Giordano A; Tagliaferri P
Cells; 2020 Aug; 9(9):. PubMed ID: 32854442
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer.
Wang J; Zheng Q; Chen J
Immunotherapy; 2023 Apr; 15(6):409-416. PubMed ID: 36950965
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
15. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
16. Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
J Natl Compr Canc Netw; 2020 Sep; 18(9):1191-1199. PubMed ID: 32886899
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
19. Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.
Quach HT; Robbins CJ; Balko JM; Chiu CY; Miller S; Wilson MR; Nelson GE; Johnson DB
Oncologist; 2019 Jul; 24(7):872-876. PubMed ID: 30936376
[TBL] [Abstract][Full Text] [Related]
20. Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients.
Izzedine H; Mathian A; Albiges L; Champiat S; Brocheriou I
Eur J Cancer; 2021 May; 149():34-36. PubMed ID: 33819719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
